Integrase strand transfer inhibitor-associated diabetes mellitus: A case report

Integrase strand transfer inhibitors (INSTIs) have become integral antiretroviral therapy (ART) agents for treating HIV infection. We report the case of a 44-year-old male with a history of hemophilia A who developed diabetes mellitus four months after switching from abacavir, lamivudine, and efavir...

Full description

Saved in:
Bibliographic Details
Published in:International journal of STD & AIDS 2017-05, Vol.28 (6), p.626-628
Main Authors: Fong, Peter S, Flynn, Devon M, Evans, Christopher D, Korthuis, P Todd
Format: Article
Language:English
Subjects:
Adult
Diabetes Mellitus - chemically induced
Diabetes Mellitus - pathology
Dideoxynucleosides - administration & dosage
Dideoxynucleosides - adverse effects
Drug Combinations
Glycated Hemoglobin A - analysis
HIV Infections - complications
HIV Infections - drug therapy
HIV Integrase Inhibitors - administration & dosage
HIV Integrase Inhibitors - adverse effects
Humans
Lamivudine - administration & dosage
Lamivudine - adverse effects
Male
Raltegravir Potassium - administration & dosage
Raltegravir Potassium - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Integrase strand transfer inhibitors (INSTIs) have become integral antiretroviral therapy (ART) agents for treating HIV infection. We report the case of a 44-year-old male with a history of hemophilia A who developed diabetes mellitus four months after switching from abacavir, lamivudine, and efavirenz to abacavir, lamivudine, and raltegravir. Hemoglobin A1C normalized without further need for exogenous insulin after raltegravir was switched back to efavirenz. In this case report, we will review a possible mechanism for INSTI-induced hyperglycemia and/or diabetes mellitus.
ISSN:0956-4624
1758-1052
DOI:10.1177/0956462416675107